Prevalencia de diabéticos controlados con hemoglobina glicosilada en dos áreas de salud. Cárdenas, 2019 / Prevalence of diabetics controlled by glycosylated hemoglobin in two health areas. Cardenas, 2019

RESUMEN Introducción: la diabetes mellitus es un trastorno metabólico caracterizado por hiperglucemia crónica con alteraciones en carbohidratos, grasas y proteínas. Debido al aumento de la morbimortalidad por diabetes, esta constituye un problema de salud en el mundo, en Cuba y en el contexto matancero. Objetivo: determinar la prevalencia de diabéticos controlados con la hemoglobina glicosilada (HbA1c), los factores asociados, y las barreras para una intervención posterior. Materiales y métodos: estudio epidemiológico, transversal, analítico a una cohorte de 601 diabéticos tipo 2 mayores de 18 años, en dos policlínicos, estudiados anteriormente. Se encuestaron y procesaron en el programa Epi-Info 7. Se obtuvieron frecuencias y proporciones de variables, prevalencia de diabéticos controlados con la hemoglobina HbA1c, los factores asociados, las comorbilidades con el OR, y las diferencias de variables entre los dos policlínicos, con el Chi2 y p < 0,05 %. Resultados: la prevalencia de diabéticos controlados fue de un 69,3 %. Las variables demográficas, comorbilidades y factores del estilo de vida no tuvieron diferencias estadísticamente significativas. Todas las variables (presencia y ausencia del factor) presentaron un control por encima del 64 %. El peso saludable, sobrepeso, enfermedades del corazón y respiratorias crónicas, ingestión de bebidas azucaradas y alimentación inadecuada, presentaron diferencias estadísticamente significativas entre los dos policlínicos. Conclusiones: No existieron diferencias entre las variables de diabéticos controlados y no controlados. Se identificaron las barreras para mejorar el control de los pacientes para una postintervención y mejorar su calidad de vida, pues un 30 % de los diabéticos no controlados presentaron algunos de los factores de riesgo estudiados (AU).

ABSTRACT Introduction: diabetes Mellitus is a metabolic disorder characterized by chronic hyperglycemia with alterations in carbohydrates, fats and proteins. Due to the increase of the morbidity and mortality rates, this is a health problem in the world, in Cuba and the province of Matanzas. Objective: to determine the prevalence of diabetics controlled with glycosylated hemoglobin (HbA1c), associated factors, and barriers to further intervention. Materials and method: an epidemiological, cross-sectional, analytical study was carried out in a cohort of 601 previously studied, type 2 diabetics over 18 years of age, in two polyclinics. The patients were surveyed and data processed in the Epi-Info 7 program. Frequencies and proportions of variables, prevalence of diabetics controlled by hemoglobin HbA1c, associated factors, comorbidities with odds ratio, as well as differences of variables between the two polyclinics were calculated by using Chi2 and p value <0.05 %. Results: the prevalence of controlled diabetics was 69.3 %. There were no statistically significant differences between demographic variables, co-morbidities and associated life style risk factors. All variables (presence and absence of the factor) showed control above 64 %. Healthy weight, overweight, heart and chronic respiratory diseases, sweet beverages intake and inadequate diet revealed statistically significant differences between the two polyclinics. Conclusions: there were no differences between the variables controlled and non-controlled diabetics. Barriers to improve patients control were identified for the sake of performing a subsequent intervention and improving their life quality, because 30 % of uncontrolled diabetic patients had some of the studied risk factors (AU).

Hemoglobina glucosilada como predictor de mortalidad y complicaciones en pacientes con infarto agudo del miocardio con elevación del segmento ST / Glycated hemoglobin as predictor of mortality and complications in patients with acute myocardial infarction with st-segment elevation

Introducción: La hemoglobina glucosilada pudiera convertirse en una herramienta en la estratificación inicial de pacientes infartados según el balance metabólico previo. Objetivo: Determinar el valor pronóstico de la hemoglobina glucosilada para muerte y complicaciones cardíacas mayores en el período intrahospitalario en pacientes con diagnóstico de infarto agudo del miocardio con elevación del segmento ST. Métodos: Se realizó un estudio observacional analítico de cohorte prospectivo en pacientes atendidos en la Unidad de Cuidados Coronarios del Hospital Universitario Arnaldo Milián Castro entre noviembre de 2018 y marzo de 2019 por presentar diagnóstico de infarto del miocardio agudo con elevación del segmento ST (N=73), de los cuales se seleccionó una muestra de 62 pacientes. Se realizó un análisis de conglomerados de K-medias y se valoró el área bajo la curva ROC de la hemoglobina glucosilada para predecir mortalidad y complicaciones mayores. Resultados: Existieron diferencias estadísticamente significativas entre los diferentes cluster en las variables estado al egreso (p=0,001; V=0,489) y ocurrencia de complicaciones cardíacas mayores (p=0,050; V=0,307). El análisis del estadístico C de la hemoglobina glucosilada demostró su capacidad predictiva para mortalidad tanto en diabéticos (C=0,810; p=0,014) como en no diabéticos (C=0,817; p=0,006), así como para complicaciones cardíacas mayores en diabéticos (C=0,799; p=0,015) y no diabéticos (C=0,683; p=0,052). Se estableció el punto de corte en 7,8 por ciento, por encima del cual la hemoglobina glucosilada constituyó un factor pronóstico de mortalidad y complicaciones cardíacas mayores. Conclusiones: Se determinó que la hemoglobina glucosilada posee capacidad para predecir mortalidad y complicaciones cardíacas mayores en el período intrahospitalario. Su valor por encima del punto de corte constituyó un predictor independiente(AU)

Introduction: Glycated hemoglobin could become a tool in the initial stratification of infarcted patients according to the previous metabolic balance. Objective: To determine the prognostic value of death glycated hemoglobin and major cardiac complications in the in-hospital period in patients diagnosed with acute myocardial infarction with ST-segment elevation. Methods: A prospective cohort analytical observational study was conducted in patients treated in the Coronary Care Unit at Arnaldo Milián Castro University Hospital from November 2018 to March 2019. They presented diagnosis of acute myocardial infarction with ST segment elevation ( N = 73); a sample of 62 patients was selected. Cluster analysis of K-means was performed and the area under ROC curve of glycated hemoglobin was assessed to predict mortality and major complications. Results: There were statistically significant differences between the clusters in the variables such as state at discharge (p = 0.001; V = 0.489) and occurrence of major cardiac complications (p = 0.050; V = 0.307). The analysis of C statistic of glycated hemoglobin established the predictive capacity for mortality in both diabetics (C = 0.810; p = 0.014) and non-diabetics (C = 0.817; p = 0.006), as well as for major cardiac complications in diabetics ( C = 0.799; p = 0.015) and non-diabetics (C = 0.683; p = 0.052). The cut-off point was established at 7.8 percent, above which glycated hemoglobin was a prognostic factor for mortality and major c. Conclusions: Glycosylated hemoglobin was stablished to have the ability to predict mortality and major cardiac complications in the in-hospital period. Its value above the cut-off point was an independent predictor(AU)

Uso de la dapagliflozina en el tratamiento de la diabetes mellitus tipo 2 / Use of dapagliflozin in the treatment of type 2 diabetes mellitus

Introducción: la dapagliflozina es un inhibidor del cotransportador sodio-glucosa tipo 2, un nuevo grupo de fármacos que disminuyen la glucemia, con bajo riesgo de hipoglucemia y con discreta pérdida de peso. Objetivo: describir algunos aspectos de interés sobre el uso de la dapagliflozina en el tratamiento de los pacientes con diabetes mellitus tipo 2, para lo cual, se realizó una revisión de varios artículos publicados sobre el tema, a través de algunas bases de datos y de los buscadores habituales (PubMed, Cochrane, Google, y otros), teniendo en cuenta su calidad y actualidad, según criterio de los autores. Desarrollo: la dapagliflozina es administrada por vía oral, e inhibe la reabsorción de glucosa en el túbulo proximal renal y aumenta la excreción urinaria de glucosa (efecto glucosúrico). Se utiliza a una dosis de 10 mg diarios, sola o asociada a otros medicamentos normo o hipoglucemiantes. En ambos casos es capaz de disminuir los niveles de la hemoglobina glucosilada. Su efectividad es similar a las sulfonilureas. Los efectos adversos más frecuentes se relacionan con un incremento de las infecciones genitourinarias, cetoacidosis con glucemias no tan elevadas, y cáncer. Conclusiones: la dapagliflozina es efectiva en reducir los niveles de la hemoglobina glucosilada, el peso corporal y de la presión arterial en pacientes con diabetes mellitus tipo 2, sobre todo, cuando se adiciona a otros medicamentos como la metformina. Su uso debe ser considerado como un tratamiento coadyuvante, aunque su indicación se debe individualizar, debido a su costo y sus posibles efectos adversos(AU)

Introduction: dapagliflozin is a sodium-glucose cotransporter 2 inhibitor, a new group of pharmaceuticals that reduce glycemia, with low risk of hypoglycemia and modest loss of weight. Objective: to describe some aspects of interest on the use of dapagliflozin in the treatment of patients with type 2 diabetes mellitus for which several articles published on this topic were reviewed through some databases and the regular searchers (PubMed, Cochrane, Google and others), taking into account their quality and topicality, according to the authors' criteria. Development: dapagliflozin is orally administered and inhibits the re-absorption of glucose in the renal proximal tubule and increases the urinary glucose excretion (glycosuric effect). The dose is 10 mg daily, single or combined with other normoglycemic and hypoglycemic drugs. In both cases, it is able to diminish the levels of glycosylate hemoglobin. The effectiveness of this new drug is similar to that of the sulfonylureas. The most frequent effects are related to increase in genitourinary infections, ketoacidosis with not so high glycemia values and cancer. Conclusions: dapagliflozin is effective for the reduction of levels of glycosylate hemoglobin, body weight and blood pressure in patients with type 2 diabetes mellitus, mainly when added to other drugs like metformin. It should be considered as a coadjuvant treatment, although it should be prescribed on an individual footing due to its cost and possible adverse effects(AU)

The level of metabolic control in low income Mexico City diabetics. The Mexico City diabetes study

The importance of good metabolic control in the treatment of diabetes mellitus (DM) is unquestionable. Measurements of the level control (LC) are available such as glycohemoglobin (GH) and fructosamine (FA). The aims of this study are: to estimate LC in a population based case series of type II DM patients, to assess the effect of clinical, metabolic and sociodemographic variables usually associated with the LC and to estimate the clinical impact of the LC on vascular complications of DM. A low income area of Mexico City was enumerated. All males and non-pregnant females between 35-64 years of age were considered eligible. Home interview was obtained in 2813 and a medical exam incluiding an oral glucose tolerance test was performed in 2282 (65.1 per cent). Three hundred and four subjects met the criteria (WHO) for DM. Three years later, 213 (70.1 per cent) were located for GH and FA measurements. Cases were divided according to the level of GH: Group I, good LC (GH < o = 8.6 per cent, n = 66); and group II poor LC (GH > o = 8.7 per cent, n = 147). A significant difference was observed in the mean vallue of FA between groups (Grop I 255 ñ 52.3 µmol/dl. Group II 306.4 ñ 51.1; p < 0.001). In compariso with subjects with good LC, patients with poor LC had higher values of duration of DM (p < 0.01), waist/hip ratio (p < 0.04), fasting glucose (p < 0.001) and lower values of fassting insulin (p < 0.07), LDL cholesterol (p < 0.006) and VLDL cholesterol (p < 0.09). Patinets with good LC had less diabetic retinophaty (p < 0.03). Around 48-69 per cent of type II urban Mexican diabetic population have poor LC. Variables usuallyt thougth to affect or be associated with LC do not influence th eend result. New therapeutic strategies in the management of DM are needed to reduce the long-term complications associated with DM